What Is in PreserVision? Active & Inactive Ingredients

PreserVision is a line of eye-health supplements made by Bausch + Lomb, built around formulations tested in two large federally funded clinical trials known as AREDS and AREDS2. The active ingredients in the current flagship product, PreserVision AREDS 2, are vitamin C, vitamin E, lutein, zeaxanthin, zinc oxide, and cupric oxide. Each plays a specific role in protecting retinal tissue from oxidative damage, and the doses were set by the clinical trials rather than by standard dietary guidelines. The inactive ingredients, which do not contribute to the supplement’s therapeutic purpose, include fillers, coatings, and colorants common to many tablets and soft gels.

The Active Ingredients and Their Doses

The PreserVision AREDS 2 formula contains six active ingredients at specific daily doses. The original AREDS trial established a combination of vitamin C at 500 mg, vitamin E at 400 IU, beta carotene at 15 mg, zinc oxide at 80 mg, and cupric oxide at 2 mg as an effective formulation for slowing progression of intermediate age-related macular degeneration (AMD) to advanced stages.¹ The AREDS2 trial then tested whether swapping beta carotene for lutein (10 mg) plus zeaxanthin (2 mg), and whether adding omega-3 fatty acids, could improve on those results.² The updated formula kept the vitamins C and E, zinc, and copper at the same doses but replaced beta carotene with lutein and zeaxanthin. It did not include omega-3s in the final recommended formulation because the trial found no additional benefit from DHA and EPA supplementation.

Here is what each active ingredient does in plain terms:

Vitamin C (500 mg): A water-soluble antioxidant that helps neutralize reactive molecules in the eye’s aqueous humor and retinal tissue. The dose in PreserVision is several times higher than what you would get from a typical multivitamin.
Vitamin E (400 IU): A fat-soluble antioxidant that protects cell membranes, including the lipid-rich photoreceptor cells in the retina, from oxidative damage.³ PreserVision uses the synthetic form (dl-alpha-tocopheryl acetate). Research has shown that the natural form of alpha-tocopherol produces higher blood and red blood cell levels than the synthetic version at equivalent doses.⁴ However, the clinical trials that validated the formula used the synthetic form, so that is what PreserVision contains.
Lutein (10 mg) and zeaxanthin (2 mg): These are carotenoid pigments that concentrate in the macula, the central part of the retina responsible for sharp, detailed vision. They filter high-energy blue light and act as antioxidants right where AMD does its damage. Supplementation with a lutein-zeaxanthin complex has been shown to significantly increase macular pigment optical density, a marker of how much protective pigment sits in the macula.⁵
Zinc oxide (80 mg): Zinc is found at high concentrations in the retina and the retinal pigment epithelium. It supports enzyme function involved in visual metabolism. The 80 mg dose is well above the recommended daily intake for zinc, which is why copper is included alongside it.
Cupric oxide (2 mg): Copper is added purely to prevent a zinc-induced copper deficiency. High doses of zinc can block copper absorption in the gut, and without supplemental copper, long-term use could lead to anemia.

Why Beta Carotene Was Removed

The original AREDS formula contained 15 mg of beta carotene, a precursor to vitamin A and a potent antioxidant. The shift to lutein and zeaxanthin in AREDS2 was driven by safety, not a lack of effectiveness. Beta carotene had been linked to increased lung cancer risk in smokers from earlier trials outside the eye field, and the AREDS2 researchers wanted a safer alternative. The ten-year follow-up of the AREDS2 cohort confirmed the concern: among former smokers randomly assigned to beta carotene, the rate of lung cancer nearly doubled compared to those assigned to lutein and zeaxanthin.⁶

The same follow-up found that the lutein-and-zeaxanthin group actually had a lower rate of progression to late AMD compared to the beta carotene group.⁶ So the swap was a win on both fronts: safer and possibly more effective. If you still see an older “PreserVision AREDS” formula on a shelf with beta carotene listed, that is the original version. Current smokers or former smokers should avoid it entirely and use the AREDS 2 version instead.

The Inactive Ingredients

Like most supplements, PreserVision contains a list of inactive ingredients that serve manufacturing and stability purposes rather than therapeutic ones. The specific inactive ingredients vary slightly depending on the product format (soft gels vs. tablets vs. chewables), but common ones across the line include:

Gelatin: Forms the shell of soft gel capsules. It is animal-derived, which matters if you follow a vegetarian or vegan diet.
Glycerin: A humectant that keeps the soft gel pliable and helps dissolve fat-soluble ingredients inside the capsule.
Soybean oil: Used as a carrier for fat-soluble vitamins and carotenoids, helping them dissolve evenly within the capsule. People with soy allergies should check the label carefully.
Titanium dioxide: A white pigment used as a coloring agent to give tablets or capsule coatings a clean, uniform appearance. It has no nutritional or therapeutic role.
Silicon dioxide: An anti-caking agent that prevents powdered ingredients from clumping during manufacturing.
Stearic acid and magnesium stearate: Lubricants that help tablets release from molds during production and allow powder to flow evenly through filling machines.

None of these inactive ingredients affect the supplement’s intended purpose. They exist to make the product physically stable, palatable, and consistent from batch to batch. Some consumers have concerns about titanium dioxide in particular, which has faced regulatory scrutiny in the European Union as a food additive. It remains permitted in supplements in the United States. If avoiding it matters to you, some competing AREDS2-based supplements are formulated without it.

How PreserVision Differs From a Standard Multivitamin

A common misconception is that any multivitamin with vitamins C and E, plus some zinc, provides the same protection as PreserVision. The doses are not remotely comparable. A typical multivitamin contains around 60 to 90 mg of vitamin C and 15 to 30 IU of vitamin E. PreserVision contains 500 mg of vitamin C and 400 IU of vitamin E, doses that are five to fifteen times higher. The zinc dose of 80 mg is also roughly five to seven times higher than what you would find in a standard multivitamin. These high doses were specifically tested in randomized trials and shown to reduce the risk of advanced AMD progression by roughly a quarter. The doses in a regular multivitamin were not studied and cannot be assumed to offer the same benefit.

On the flip side, PreserVision is not a multivitamin replacement. It does not contain vitamin D, vitamin A (as preformed retinol), B vitamins, calcium, iron, or most other nutrients people associate with a daily multi. Taking PreserVision alongside a multivitamin is common practice, but you should watch the total zinc and vitamin E intake from both products combined, especially if you are also eating fortified foods.

Why the Zinc Dose Is Controversial

The 80 mg zinc dose in PreserVision is one of its most debated features. The tolerable upper intake level for zinc set by nutrition authorities is 40 mg per day for adults. PreserVision delivers double that. The AREDS2 trial actually tested whether a lower zinc dose of 25 mg could match the effectiveness of 80 mg, and both arms performed similarly for AMD outcomes.⁷ Despite this, the marketed PreserVision AREDS 2 formula retained the 80 mg dose. Some ophthalmologists now suggest that the 25 mg version would be adequate for most patients, with fewer gastrointestinal side effects.

High-dose zinc can cause nausea, stomach cramps, and reduced appetite. A study of zinc sulfate (a different zinc salt, not zinc oxide) in children with a genetic condition found gastrointestinal side effects in about 40% of patients, including some with erosions in the upper digestive tract.⁸ That study used zinc sulfate for a different medical condition and in a different population, so the numbers do not translate directly to adults taking zinc oxide in PreserVision. But the broader point holds: high-dose zinc is not trivial for the gut, and the copper included in the formula does not protect against digestive irritation. If you have persistent stomach trouble on PreserVision, talk to your eye doctor about whether a lower-zinc version makes sense for you.

Vitamin E at 400 IU and Stroke Risk

The 400 IU vitamin E dose in PreserVision has also attracted scrutiny. A meta-analysis of randomized trials found that vitamin E supplementation was associated with a modest increase in the risk of hemorrhagic stroke, with about one additional case per 1,250 people taking the supplement.⁹ At the same time, vitamin E was linked to a reduction in ischemic stroke, the more common type, preventing roughly one case per 476 people.⁹ The net effect on total stroke risk was essentially zero. For most people, this tradeoff is not clinically meaningful. But if you have a condition that increases bleeding risk, or if you take blood thinners, the hemorrhagic stroke signal is worth discussing with a doctor before starting a supplement containing 400 IU of vitamin E daily.

Your Genes May Change How the Formula Works

One of the more striking findings from post-hoc analyses of the AREDS data is that the supplement’s benefit varies significantly based on a person’s genetic makeup. Two genes in particular, CFH and ARMS2, appear to influence whether the antioxidant and zinc components help, do nothing, or potentially cause harm. Patients carrying risk variants in the ARMS2 gene appeared to benefit most from zinc-containing regimens, while patients carrying two risk variants in the CFH gene without ARMS2 risk alleles actually progressed faster on zinc-containing treatment compared to placebo.¹⁰

In one analysis, patients with two CFH risk alleles and no ARMS2 risk alleles had a seven-year AMD progression rate of about 17% on placebo but over 40% on zinc-containing treatments, a striking reversal of the expected benefit.¹⁰ Meanwhile, patients with ARMS2 risk alleles and low CFH risk saw their progression rate cut roughly in half with zinc-containing treatments. Another analysis found that individuals carrying CFH risk alleles derived the most benefit from antioxidants alone, and the addition of zinc actually negated that benefit.¹¹

These findings are from post-hoc analyses, meaning the original trials were not designed to test genetic subgroups. The results have not yet led to routine genetic testing before prescribing AREDS supplements, and major ophthalmology organizations still recommend the standard AREDS2 formulation for eligible patients regardless of genotype. But the research suggests that a one-size-fits-all approach may eventually give way to genotype-guided supplementation. If you are interested in this, some direct-to-consumer genetic tests now report CFH and ARMS2 variants, though interpreting the results requires a conversation with a retina specialist.

PreserVision Is Not FDA-Approved

PreserVision is classified as a dietary supplement, not a drug. That distinction has real consequences. It has not been evaluated or approved by the FDA for diagnosing, treating, curing, or preventing any disease.¹² Dietary supplements in the United States are regulated under a different framework than pharmaceuticals. Manufacturers are responsible for ensuring their products are safe and that label claims are truthful, but they are not required to prove efficacy to the FDA before selling the product. There is no pre-market approval process.

This does not mean PreserVision is untested. The active ingredients and their doses were validated in the AREDS and AREDS2 trials, which were rigorous, large-scale, federally funded randomized clinical trials. Few supplements can point to evidence of that caliber. But the regulatory classification means there is less independent oversight of manufacturing consistency than there would be for a prescription drug. If consistency matters to you, look for supplements that carry a USP (United States Pharmacopeia) verification mark or have been tested by an independent third-party lab like NSF International or ConsumerLab.

Who Should and Should Not Take It

PreserVision was designed for a specific patient population: people with intermediate AMD or advanced AMD in one eye. The clinical trials enrolled adults with these conditions, and the proven benefit applies to slowing progression in these groups. PreserVision is not proven to prevent AMD from developing in the first place, and it is not proven to help people with early AMD or no AMD at all. Taking it “just in case” means accepting the costs and potential side effects of high-dose zinc and vitamin E supplementation without evidence that you are getting any protective benefit.

People who should be especially cautious include current or recent smokers (who should avoid any formula still containing beta carotene), anyone on blood-thinning medication (due to the vitamin E dose), and anyone with kidney disease (high-dose zinc can accumulate when kidney function is impaired). Pregnant or breastfeeding women were not included in the AREDS trials, and the high vitamin and mineral doses have not been studied in that context. The most sensible path is to get a dilated eye exam, find out whether you actually have the stage of AMD that the supplement was tested for, and discuss the decision with your eye care provider.

The Newer AREDS3 Formulation

Bausch + Lomb has recently launched a product called PreserVision AREDS3, which modifies the AREDS2 formula. The details of AREDS3 are still emerging, but the move signals ongoing interest in refining the supplement based on newer research into nutrients like meso-zeaxanthin and other carotenoids that were not part of the original trials. Like its predecessors, AREDS3 is marketed as a dietary supplement and has not been evaluated by the FDA for disease prevention or treatment.¹² Whether the updated formula performs better than the AREDS2 version in long-term clinical outcomes remains to be seen, as no large randomized trial comparable to AREDS or AREDS2 has been completed for the new formulation. For now, the AREDS2 formula remains the most thoroughly validated version on the market.